Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Healthcare Biotechnology
Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and... see more

Recent & Breaking News (TSX:ONC)

Oncolytics Biotech® Announces Proposed Public Offering

Canada NewsWire May 23, 2017

Oncolytics Biotech® Inc. Announces Participation in World Immunotherapy Congress USA 2017

PR Newswire May 23, 2017

Oncolytics Biotech® Announces ASCO Abstracts and Preliminary Data for Studies in Pancreatic and Prostate Cancers

Canada NewsWire May 17, 2017

Oncolytics Biotech® Inc. Announces FDA Fast Track Designation for REOLYSIN® in Metastatic Breast Cancer

Canada NewsWire May 8, 2017

Oncolytics Biotech® Inc. Announces 2017 First Quarter Results

Canada NewsWire May 5, 2017

Oncolytics Biotech® Inc. Announces Voting Results from its Annual Meeting of Shareholders

Canada NewsWire May 4, 2017

Oncolytics Biotech® Inc. Announces Details of 2017 Annual Meeting of Shareholders

PR Newswire April 27, 2017

Oncolytics Biotech® Inc. to Present at the Sixth Annual Bloom Burton & Co. Healthcare Investor Conference

Canada NewsWire April 26, 2017

Oncolytics Biotech® Inc. Announces Registration Pathway and Clinical Development Plan

Canada NewsWire April 12, 2017

Oncolytics Biotech® Inc.'s REOLYSIN® More than Doubles Overall Survival in Patients with Mutated p53 Metastatic Breast Cancer

Canada NewsWire April 5, 2017

IIROC Trade Resumption - Oncolytics Biotech Inc.

Newsfile April 3, 2017

IIROC Trading Halt - ONC (all issues)

Canada NewsWire March 31, 2017

IIROC Trade Halt - Oncolytics Biotech Inc.

Newsfile March 31, 2017

Oncolytics Biotech® Inc.'s REOLYSIN® Provides Statistically Significant Improvement in Overall Survival in Canadian Cancer Trials Group Sponsored Randomized Phase 2 Study in Metastatic Breast Cancer

Canada NewsWire March 31, 2017

Oncolytics Biotech® Inc. Enters into First-in-Class Collaboration with Myeloma UK and Celgene Using REOLYSIN® in Combination with Imnovid® or Revlimid® in Patients with Myeloma

Canada NewsWire March 16, 2017

Oncolytics Biotech® Inc. Announces 2016 Year-End Results

Canada NewsWire March 10, 2017

Oncolytics Biotech® Inc. Announces Canadian Cancer Trials Group to Present Final Randomized Data from Phase 2 Metastatic Breast Cancer Study at AACR 2017 Annual Meeting

Canada NewsWire March 2, 2017

Oncolytics Biotech® Inc. Appoints Dr. Matt Coffey to the Role of President and CEO

Canada NewsWire January 19, 2017

Oncolytics Biotech® Inc. Announces Change to Board of Directors

PR Newswire December 6, 2016

Oncolytics Biotech® Inc. Collaborators Present Initial Results from REO 019 Study in Multiple Myeloma Combining REOLYSIN®, Bortezomib and Dexamethasone at the ASH Annual Meeting

PR Newswire December 6, 2016